Skp2 in androgen-dependent proliferation of prostate cancer cells
Skp2 in androgen-dependent proliferation of prostate cancer cells
批准号:
7585477
负责人:
LIANG ZHU
金额:
$31.0万
依托单位国家:
美国
项目类别:
财政年份:
2009
资助国家:
美国
项目状态:
已结题
起止时间:
2009-07-01 至 2013-05-31
关键词:
AblationAndrogen ReceptorAndrogensBiologyCancer BiologyCastrationCell ProliferationDependenceDiseaseDisease ProgressionEpitheliumExperimental ModelsF-Box ProteinsFoundationsHumanLeadLightMalignant neoplasm of prostateMediatingMolecularOncogenicPopulationPropertyProstateReceptor SignalingRecurrenceRefractoryRegulationResearchRoleSkp2 ProteinsStagingTestingXenograft ModelXenograft procedureandrogen independent prostate cancercancer cellcancer cell differentiationcancer diagnosiskillingsmalemenmouse modelpublic health relevancereceptor functiontreatment strategytumortumor growth
中文摘要
点击翻译按钮获取中文摘要
英文摘要
DESCRIPTION (provided by applicant): Prostate cancer has become the most common male cancer diagnosed in Western populations. Prostate cancer generally starts in an androgen-dependent (AD) form, which can be effectively treated with androgen ablation therapies. Androgen ablation therapies however almost always lead to more aggressive androgen-independent (AI) forms of the disease. Most research on this important issue has focused on identifying cellular and molecular changes in disease progression from AD to AI. In this application, we propose instead to focus on understanding how androgen-androgen receptor (AR) functions to promote proliferation of AD prostate cancer cells. Androgen-AR promotes both proliferation and differentiation of AD prostate cancer cells. We believe that a better understanding of how androgen-AR promotes proliferation of AD prostate cancer cells will shed light on how to specifically target the proliferation-promoting function of AR, which may lead to new treatment for AD prostate cancer that does not compromise cancer cell differentiation. This will establish a new paradigm of treating AD prostate cancer as compared to androgen ablation therapy, which inhibits both proliferation and differentiation of AD prostate cancer cells. Since functions of AR have been found important for at least some androgen-independent (AI) prostate cancer, targeting the proliferation-promoting functions of AR will impact on the treatment of AI prostate cancer as well, which is current incurable. Our hypothesis to be tested in this application is that the F-box protein Skp2 is an important downstream effector of AR in mediating proliferation of AD and some AI prostate cancer cells independently of their differentiation, and specifically targeting Skp2 represents a new concept in treatment of AD and some AI prostate cancer. In Specific Aim 1, we will determine the molecular mechanisms underlying the regulation of Skp2 by AR. In Specific Aim 2, we will determine the regulation of Skp2 by androgen in human AD prostate cancer xenografts and determine and compare the effects of castration and Skp2 knockdown on xenograft tumor growth and recurrence. Finally in Specific Aim 3, we will use mouse models to determine the role of Skp2 in prostate epithelium proliferation and transformation induced by oncogenic levels of AR, which is a suspected cause of prostate cancer in humans.
PUBLIC HEALTH RELEVANCE: Prostate cancer has become the most common male cancer diagnosed in Western populations. A fundamental property of prostate cancer is its initial androgen-dependence and inevitable progression to lethal androgen-independent forms of the disease. This project aims to understand how the androgen receptor promotes prostate cancer and to develop targeted treatment strategy for prostate cancer.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Skp2 in androgen-dependent proliferation of prostate cancer cells
-
批准号:8084180
-
项目类别:
-
资助金额:$30.07万
-
财政年份:2009
-
负责人:LIANG ZHU
-
依托单位:
Role of Skp2-cyclin A Interaction in Normal Physiology and Cancer
-
批准号:8403894
-
项目类别:
-
资助金额:$28.27万
-
财政年份:2009
-
负责人:LIANG ZHU
-
依托单位:
Role of Skp2-cyclin A Interaction in Normal Physiology and Cancer
-
批准号:8207286
-
项目类别:
-
资助金额:$30.07万
-
财政年份:2009
-
负责人:LIANG ZHU
-
依托单位:
Role of Skp2-cyclin A Interaction in Normal Physiology and Cancer
-
批准号:7777365
-
项目类别:
-
资助金额:$31.0万
-
财政年份:2009
-
负责人:LIANG ZHU
-
依托单位:
Role of Skp2-cyclin A Interaction in Normal Physiology and Cancer
-
批准号:8009512
-
项目类别:
-
资助金额:$30.07万
-
财政年份:2009
-
负责人:LIANG ZHU
-
依托单位:
Skp2 in androgen-dependent proliferation of prostate cancer cells
-
批准号:7880645
-
项目类别:
-
资助金额:$31.0万
-
财政年份:2009
-
负责人:LIANG ZHU
-
依托单位:
Skp2 in androgen-dependent proliferation of prostate cancer cells
-
批准号:8324019
-
项目类别:
-
资助金额:$30.07万
-
财政年份:2009
-
负责人:LIANG ZHU
-
依托单位:
Role of Skp2-cyclin A Interaction in Normal Physiology and Cancer
-
批准号:7655681
-
项目类别:
-
资助金额:$31.0万
-
财政年份:2009
-
负责人:LIANG ZHU
-
依托单位:
P27Kip1 in Hepatocyte Proliferation
-
批准号:6767616
-
项目类别:
-
资助金额:$28.64万
-
财政年份:2002
-
负责人:LIANG ZHU
-
依托单位:
P27Kip1 in Hepatocyte Proliferation
-
批准号:6653779
-
项目类别:
-
资助金额:$28.64万
-
财政年份:2002
-
负责人:LIANG ZHU
-
依托单位:
P27Kip1 in Hepatocyte Proliferation
-
批准号:6918746
-
项目类别:
-
资助金额:$28.64万
-
财政年份:2002
-
负责人:LIANG ZHU
-
依托单位:
P27Kip1 in Hepatocyte Proliferation
-
批准号:6543616
-
项目类别:
-
资助金额:$32.4万
-
财政年份:2002
-
负责人:LIANG ZHU
-
依托单位:
P27Kip1 in Hepatocyte Proliferation
-
批准号:7080393
-
项目类别:
-
资助金额:$27.97万
-
财政年份:2002
-
负责人:LIANG ZHU
-
依托单位:
P27kip1 as an early effector of pRB function
-
批准号:6633793
-
项目类别:
-
资助金额:$26.3万
-
财政年份:2001
-
负责人:LIANG ZHU
-
依托单位:
P27kip1 as an early effector of pRB function
-
批准号:6722866
-
项目类别:
-
资助金额:$26.3万
-
财政年份:2001
-
负责人:LIANG ZHU
-
依托单位:
P27kip1 as an early effector of pRB function
-
批准号:6514666
-
项目类别:
-
资助金额:$26.32万
-
财政年份:2001
-
负责人:LIANG ZHU
-
依托单位:
P27kip1 as an early effector of pRB function
-
批准号:6333299
-
项目类别:
-
资助金额:$26.38万
-
财政年份:2001
-
负责人:LIANG ZHU
-
依托单位:
海外基金